Cimeio Therapeutics

Transforming cell and gene therapy through leadership in the emerging field of epitope shielding

[Cimeio Therapeutics @Cimeio]

This therapy has the potential to be a universal treatment for patients with blood cancers, and significantly improve the outcomes for those hardest to treat forms such as AML.

[Cimeio Therapeutics @Cimeio]

Congratulations to our founder Lukas Jeker, Romina Matter-Marone and the teams at @Jekerlab and @Cimeio on the publication of their work on CD45 in this week’s issue of @Nature.

https://t.co/QSNNSQ4R4c

[Cimeio Therapeutics @Cimeio]

They have demonstrated that its possible to safely administer a highly effective CD45 ADC to eliminate aggressive leukemia cells in mice, while preserving hematopoiesis through the administration of CD45 epitope shielded HSCs.

[Cimeio Therapeutics @Cimeio]

This program serves as the basis for a novel treatment approach for patients with T cell malignancies, and aiding in improving the durability of allogeneic CAR T cells.

[Cimeio Therapeutics @Cimeio]

For those attending this week's hashtag#ASGCT meeting, please join our CSO Stefanie Urlinger at poster no. 1778 beginning at 5:30 PM on Friday, where she will be presenting the first data on our CD52 program.
https://t.co/6PlGzoZ3S1

[Cimeio Therapeutics @Cimeio]

Links to abstracts
https://t.co/XWyGaYYEuz
https://t.co/EiB8KsAdsc

[Cimeio Therapeutics @Cimeio]

This weekend we presented data at #ASH23 for our CD45 program, showing full tumor eradication in an aggressive AML cell line in vivo. These data serve as POC for a program that could one day transform the treatment of AML
https://t.co/qmpX9CaYZn

[Cimeio Therapeutics @Cimeio]

In the second, we demonstrate how our epitope edited CD33 HSCs are shielded from CD33 directed immunotherapy depletion. CD33 represents the fourth target we have epitope edited to prevent paired immunotherapy depletion while maintaining its function.

[Cimeio Therapeutics @Cimeio]

We are pleased to announce that we will be presenting two posters at this year’s ASH meeting. In the first, we demonstrate that our CD45 ADC effectively depletes AML cells, while our shielded HSCs are fully protected. #ASH23
https://t.co/kAIfsabsd5

[Cimeio Therapeutics @Cimeio]

Today we announced a collaboration with Saar Gill and @carlhjune at @PennMedicine to develop and test a CD45 CAR T cell that pairs with our CD45 shielded HSCs. This ‘Universal CAR T’ could be used to treat any type of blood cancer or autoimmune disease.
https://t.co/p9UIe67YpI

[Cimeio Therapeutics @Cimeio]

@PrimeMedicine This collaboration brings together industry leading protein engineering and genome editing, with the potential to deliver safer, curative therapies for patients

[Cimeio Therapeutics @Cimeio]

We are very pleased to announce a research collaboration with @PrimeMedicine to develop CD117 shielded products for AML/MDS and rare genetic diseases (ex-SCD). https://t.co/xolvzctoTm

[Cimeio Therapeutics @Cimeio]

This program could serve as a universal approach to reset the hematopoietic system for hematologic malignancies or severe autoimmune diseases.

[Cimeio Therapeutics @Cimeio]

We are pleased to present the first data from our CD45 shielded cell program at this week's #ASGCT meeting in Los Angeles. The poster number is 899, and will be presented from 12:00-2:00 PT on Thursday, May 18. https://t.co/5PYJ60OL4g

[Cimeio Therapeutics @Cimeio]

Our in vivo data showed efficient engraftment and differentiation of our engineered CD45 engineered HSCs, as well as shielding and strong enrichment in combination with our CD45 immunotherapy.

[Cimeio Therapeutics @Cimeio]

A hearty congratulations to Jeff for this well deserved recognition! https://t.co/H4zO2k8uM4

[Diabetes Center at UCSF @AtUcsf]

Founding Director and Professor Emeritus Jeff Bluestone has been elected into the National Academy of Sciences @theNASciences a testament to the major contributions to the fields of immunology and diabetes that he has made over his career

[Cimeio Therapeutics @Cimeio]

Very nice @biocentury article covering the emerging cellular shielding field, including @cimeio's recent abstracts for CD117 and CD123, along with those for @BeamTx, @carlhjune, and @Genovese_Lab

[Cimeio Therapeutics @Cimeio]

Congratulations to Romina Matter and Emmanuelle Landmann for presenting our first data demonstrating proof-of-concept for our SCIP platform this weekend at #ASH2022!

https://t.co/G4m9YeT8mE

[Cimeio Therapeutics @Cimeio]

Excited to announce that we've been granted broad IP that covers the shielding of cells from immunotherapy depletion. This foundational IP protects our SCIP platform and enables us to develop curative therapies for patients with life threatening diseases
https://t.co/MaXPKBMOui

[Cimeio Therapeutics @Cimeio]

We're very pleased to present the first data for our SCIP (Shielded Cell & Immunotherapy Pairs) platform at #ASH2022. Two abstracts covering our CD117 and CD123 programs demonstrate POC in vivo and serve as the basis for a broad development pipeline. https://t.co/KUmUlKMsTF